Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-Induced Gene Expression in HCV (Caucasian vs African American)
NCT00324389Phase 2
Key facts
- Status
- Completed
- Start
- May 2006
- Countries
- 1
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- rProtein (Recombinant Protein), Biologic
- Drugs
- interferon alfa-2a
- Conditions
- hepatitis C (HCV)
01
Overview
Phase 2, open-label trial of interferon alfa-2a in hepatitis C (HCV), sponsored by National Institute of Allergy and Infectious Diseases. Started May 2006; status: completed.
02
Design
- Study design
- Non-randomizedOpen-label
03
Registry description
This proposal seeks to use DNA analyses to understand how racial and genetic factors influence interferon (treatment) response in HCV infection in African Americans. A better understanding should allow rational design of new therapies or better use of existing therapies. Patients will provide medical history and undergo a physical exam, blood draws, electrocardiogram, possible chest x-ray, and abdominal ultrasound. Patients will be admitted to the hospital for 5 days and undergo 2 liver biopsies, sedation, and multiple blood draws. Twenty adult male volunteers (10 Caucasians,10 African…
Beyond the preview
Go deeper on NCT00324389.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00324389.